Skip to Main Content

Advertisement

Umbrella Alt Text
header search
Search
Advanced Search
Skip Nav Destination

A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia

Clin Cancer Res (2019) 25 (14): 4231–4237.
This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.
Targeting the bone marrow niche, moving towards leukemia eradication
  • Carla Semedo
  • Raquel Caroço
  • António Almeida
  • Bruno António Cardoso
Frontiers in Hematology (2024) 3
A Transcription Factor ZNF384, Regulated by LINC00265, Activates the Expression of IFI30 to Stimulate Malignant Progression in Glioma
  • Jian Yang
  • Shenghe Yang
  • Jinlian Cai
  • Hongjin Chen
  • Lihua Sun
  • Jiajia Wang
  • Guoqiang Hou
  • Shuo Gu
  • Jie Ma
  • Jianwei Ge
ACS Chemical Neuroscience (2024) 15 (2): 290.
Interferon Gamma Inducible Protein 30: from biological functions to potential therapeutic target in cancers
  • Sen Zhang
  • Liwen Ren
  • Wan Li
  • Yizhi Zhang
  • Yihui Yang
  • Hong Yang
  • Fang Xu
  • Wanxin Cao
  • Xiaoxue Li
  • Xu Zhang
  • Guanhua Du
  • Jinhua Wang
Cellular Oncology (2024) 47 (5): 1593.
Hematopoietic and leukemic stem cells homeostasis: the role of bone marrow niche
  • Shaimaa Khattab
  • Manal El Sorady
  • Ashraf El-Ghandour
  • Giuseppe Visani
  • Pier Paolo Piccaluga
Exploration of Targeted Anti-tumor Therapy (2024) 5 (5): 1027.
Biology and Therapeutic Properties of Mesenchymal Stem Cells in Leukemia
  • Cheng-Hsien Wu
  • Te-Fu Weng
  • Ju-Pi Li
  • Kang-Hsi Wu
International Journal of Molecular Sciences (2024) 25 (5): 2527.
In vivo activity of the second-generation proteasome inhibitor ixazomib against pediatric T-cell acute lymphoblastic leukemia xenografts
  • Joanna Randall
  • Kathryn Evans
  • Ben Watts
  • Hansen J. Kosasih
  • Christopher M. Smith
  • Eric J. Earley
  • Stephen W. Erickson
  • Emily L. Jocoy
  • Carol J. Bult
  • Beverly A. Teicher
  • Charles E. de Bock
  • Malcolm A. Smith
  • Richard B. Lock
Experimental Hematology (2024) 132: 104176.
Deubiquitinases as novel therapeutic targets for diseases
  • Yali Xian
  • Jing Ye
  • Yu Tang
  • Nan Zhang
  • Cheng Peng
  • Wei Huang
  • Gu He
MedComm (2024) 5 (12)
Modified isotonic regression based phase I/II clinical trial design identifying optimal biological dose
  • Yingjie Qiu
  • Yi Zhao
  • Hao Liu
  • Sha Cao
  • Chi Zhang
  • Yong Zang
Contemporary Clinical Trials (2023) 127: 107139.
Current trends and challenges in the mitoxantrone measuring in biofluids and new pharmaceutical systems
  • Olga A. Goryacheva
  • Pavel S. Pidenko
  • Alexey V. Markin
  • Natalia E. Markina
  • Daria V. Tsyupka
  • Ekaterina A. Mordovina
  • Tatiana D. Ponomaryova
  • Svetlana A. Meshcheryakova
  • Danila A. Kornilov
  • Pavel D. Strokin
  • Daniil D. Drozd
  • Yuliya A. Podkolodnaya
  • Anastasia A. Kovyrshina
  • Irina V. Morozova
  • Tatiana V. Shelekhova
  • Irina Yu Goryacheva
TrAC Trends in Analytical Chemistry (2023) 169: 117373.
Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia: An Overview of Systematic Reviews
  • Peijie He
  • Juan Liang
  • Wanjun Zhang
  • Shengyun Lin
  • Hanting Wu
  • Qiushuang Li
  • Xiujuan Xu
  • Conghua Ji
  • Pier Paolo Piccaluga
International Journal of Clinical Practice (2022) 2022: 1.
Glutathione-Mediated Conjugation of Anticancer Drugs: An Overview of Reaction Mechanisms and Biological Significance for Drug Detoxification and Bioactivation
  • Agnieszka Potęga
Molecules (2022) 27 (16): 5252.
Hallmark-guided subtypes of hepatocellular carcinoma for the identification of immune-related gene classifiers in the prediction of prognosis, treatment efficacy, and drug candidates
  • Chengbin Guo
  • Yuqin Tang
  • Zhao Yang
  • Gen Li
  • Yongqiang Zhang
Frontiers in Immunology (2022) 13
High GILT Expression Is Associated with Improved Survival in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibition
  • Anngela C. Adams
  • Elizabeth S. Borden
  • Anne M. Macy
  • Nick Thomson
  • Haiyan Cui
  • Mark I. Gimbel
  • Melissa A. Wilson
  • Kenneth H. Buetow
  • Denise J. Roe
  • David J. DiCaudo
  • Jade Homsi
  • Karen Taraszka Hastings
Cancers (2022) 14 (9): 2200.
Regulation of Malignant Myeloid Leukemia by Mesenchymal Stem Cells
  • Zhenya Tan
  • Chen Kan
  • Mandy Wong
  • Minqiong Sun
  • Yakun Liu
  • Fan Yang
  • Siying Wang
  • Hong Zheng
Frontiers in Cell and Developmental Biology (2022) 10
Efficacy and safety of mitoxantrone hydrochloride liposome injection in Chinese patients with advanced breast cancer: a randomized, open-label, active-controlled, single-center, phase II clinical trial
  • Leiping Wang
  • Jun Cao
  • Chunlei Li
  • Xiaodong Wang
  • Yannan Zhao
  • Ting Li
  • Yiqun Du
  • Zhonghua Tao
  • Wenxia Peng
  • Biyun Wang
  • Jian Zhang
  • Sheng Zhang
  • Zhonghua Wang
  • Xichun Hu
Investigational New Drugs (2022) 40 (2): 330.
CLEC12A plays an important role in immunomodulatory function and prognostic significance of patients with acute myeloid leukemia
  • Qiaoqiao Li
  • Chunyan Liang
  • Xintong Xu
  • Congli Zhang
  • Weijie Cao
  • Meng Wang
  • Zhongxing Jiang
  • Haizhou Xing
  • Jifeng Yu
Leukemia & Lymphoma (2022) 63 (9): 2136.
Comparison of the impact of two post-remission therapy regimens on cardiac events in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation
  • Jin Hayakawa
  • Hideki Nakasone
  • Daisuke Minakata
  • Shin-ichiro Fujiwara
  • Ayumi Gomyo
  • Yu Akahoshi
  • Yusuke Komiya
  • Naonori Harada
  • Tomotaka Ugai
  • Kazuaki Kameda
  • Hidenori Wada
  • Yuko Ishihara
  • Koji Kawamura
  • Kana Sakamoto
  • Miki Sato
  • Kiriko Terasako-Saito
  • Misato Kikuchi
  • Shun-ichi Kimura
  • Junya Kanda
  • Shinichi Kako
  • Yoshinobu Kanda
International Journal of Hematology (2022) 116 (2): 239.
Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
  • Joshua F. Zeidner
  • Benjamin G. Vincent
  • Anastasia Ivanova
  • Dominic Moore
  • Karen P. McKinnon
  • Alec D. Wilkinson
  • Rupkatha Mukhopadhyay
  • Francesco Mazziotta
  • Hanna A. Knaus
  • Matthew C. Foster
  • Catherine C. Coombs
  • Katarzyna Jamieson
  • Hendrik Van Deventer
  • Jonathan A. Webster
  • Gabrielle T. Prince
  • Amy E. DeZern
  • B. Douglas Smith
  • Mark J. Levis
  • Nathan D. Montgomery
  • Leo Luznik
  • Jonathan S. Serody
  • Ivana Gojo
Blood Cancer Discovery (2021) 2 (6): 616.
Proteasome Inhibitors Interrupt the Activation of Non-Canonical NF-κB Signaling Pathway and Induce Cell Apoptosis in Cytarabine-Resistant HL60 Cells
  • Shuo-Yu Wang
  • Yin-Hwa Shih
  • Tzong-Ming Shieh
  • Yu-Hsin Tseng
International Journal of Molecular Sciences (2021) 23 (1): 361.
Recent Research Progress of Chiral Small Molecular Antitumor-Targeted Drugs Approved by the FDA From 2011 to 2019
  • Xuetong Chu
  • Yizhi Bu
  • Xiaoping Yang
Frontiers in Oncology (2021) 11
Adrenomedullin Expression Characterizes Leukemia Stem Cells and Associates With an Inflammatory Signature in Acute Myeloid Leukemia
  • Giorgia Simonetti
  • Davide Angeli
  • Elisabetta Petracci
  • Eugenio Fonzi
  • Susanna Vedovato
  • Alessandra Sperotto
  • Antonella Padella
  • Martina Ghetti
  • Anna Ferrari
  • Valentina Robustelli
  • Rosa Di Liddo
  • Maria Teresa Conconi
  • Cristina Papayannidis
  • Claudio Cerchione
  • Michela Rondoni
  • Annalisa Astolfi
  • Emanuela Ottaviani
  • Giovanni Martinelli
  • Michele Gottardi
Frontiers in Oncology (2021) 11
Proteasome inhibitors suppress MYB oncogenic activity in a p300-dependent manner
  • Maria V. Yusenko
  • Abhiruchi Biyanee
  • Mattias K. Andersson
  • Silke Radetzki
  • Jens P. von Kries
  • Göran Stenman
  • Karl-Heinz Klempnauer
Cancer Letters (2021) 520: 132.
Oral Proteasome Inhibitor Ixazomib for Switch-Maintenance Prophylaxis of Recurrent or Late Acute and Chronic Graft-versus-Host Disease after Day 100 in Allogeneic Stem Cell Transplantation
  • Natasia Rodriguez
  • Jasme Lee
  • Lisa Flynn
  • Fiona Murray
  • Sean M. Devlin
  • Cristina Soto
  • Christina Cho
  • Parastoo Dahi
  • Sergio Giralt
  • Miguel-Angel Perales
  • Craig Sauter
  • Doris M. Ponce
Transplantation and Cellular Therapy (2021) 27 (11): 920.e1.
Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells
  • Margot S.F. Roeten
  • Johan van Meerloo
  • Zinia J. Kwidama
  • Giovanna ter Huizen
  • Wouter H. Segerink
  • Sonja Zweegman
  • Gertjan J.L. Kaspers
  • Gerrit Jansen
  • Jacqueline Cloos
Cells (2021) 10 (3): 665.
Successful ixazomib treatment for relapsed and refractory acute myeloid leukemia transformed from myelodysplastic syndrome
  • Satoko Oka
  • Kazuo Ono
Clinical Case Reports (2021) 9 (6)
Targeting IFN-γ-inducible lysosomal thiol reductase overcomes chemoresistance in AML through regulating the ROS-mediated mitochondrial damage
  • Li-Ting Niu
  • Yu-Qing Wang
  • Catherine C.L. Wong
  • Shuai-Xin Gao
  • Xiao-Dong Mo
  • Xiao-Jun Huang
Translational Oncology (2021) 14 (9): 101159.
Therapeutic Targeting of the Leukaemia Microenvironment
  • Vincent Kuek
  • Anastasia M. Hughes
  • Rishi S. Kotecha
  • Laurence C. Cheung
International Journal of Molecular Sciences (2021) 22 (13): 6888.
Leukemia Stem Cell Release From the Stem Cell Niche to Treat Acute Myeloid Leukemia
  • Alicia Villatoro
  • Joanna Konieczny
  • Vincent Cuminetti
  • Lorena Arranz
Frontiers in Cell and Developmental Biology (2020) 8
Deubiquitinating Enzyme-Mediated Signaling Networks in Cancer Stem Cells
  • Kamini Kaushal
  • Suresh Ramakrishna
Cancers (2020) 12 (11): 3253.
A phase 1 study of the antibody‐drug conjugate brentuximab vedotin with re‐induction chemotherapy in patients with CD30‐expressing relapsed/refractory acute myeloid leukemia
  • Rupa Narayan
  • Traci M. Blonquist
  • Ashkan Emadi
  • Robert P. Hasserjian
  • Meghan Burke
  • Christopher Lescinskas
  • Donna S. Neuberg
  • Andrew M. Brunner
  • Gabriela Hobbs
  • Hanno Hock
  • Steven L. McAfee
  • Yi‐Bin Chen
  • Eyal Attar
  • Timothy A. Graubert
  • Christina Bertoli
  • Jenna A. Moran
  • Meghan K. Bergeron
  • Julia E. Foster
  • Aura Y. Ramos
  • Tina T. Som
  • Megan K. Vartanian
  • Jennifer L. Story
  • Kristin McGregor
  • Molly Macrae
  • Tanya Behnan
  • Margaret C. Wey
  • Jessica Rae
  • Frederic I. Preffer
  • Patricia Lesho
  • Vu H. Duong
  • Mason L. Mann
  • Karen K. Ballen
  • Christine Connolly
  • Philip C. Amrein
  • Amir T. Fathi
Cancer (2020) 126 (6): 1264.
Advances in Deubiquitinating Enzyme Inhibition and Applications in Cancer Therapeutics
  • Ainsley Mike Antao
  • Apoorvi Tyagi
  • Kye-Seong Kim
  • Suresh Ramakrishna
Cancers (2020) 12 (6): 1579.
BOIN12: Bayesian Optimal Interval Phase I/II Trial Design for Utility-Based Dose Finding in Immunotherapy and Targeted Therapies
  • Ruitao Lin
  • Yanhong Zhou
  • Fangrong Yan
  • Daniel Li
  • Ying Yuan
JCO Precision Oncology (2020) (4): 1393.
Drug Development Targeting the Ubiquitin–Proteasome System (UPS) for the Treatment of Human Cancers
  • Xiaonan Zhang
  • Stig Linder
  • Martina Bazzaro
Cancers (2020) 12 (4): 902.
  • Online ISSN 1557-3265
  • Print ISSN 1078-0432

AACR Journals

 

 

  • Copyright © 2025 by the American Association for Cancer Research.
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.
Accept